Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 41.39% is 675% above its 5-year average of -7.20%, near the high end of its 5-year range (-72.39%–56.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.00% below its 12-month average of 43.11%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 41.39%.
RETURN ON EQUITY (ROE)
41.39%
RETURN ON EQUITY (ROE) AVG TTM
43.11%
RETURN ON EQUITY (ROE) AVG 3Y
23.82%
RETURN ON EQUITY (ROE) AVG 5Y
-7.20%
RETURN ON EQUITY (ROE) AVG 10Y
-56.79%
RETURN ON EQUITY (ROE) AVG 15Y
-82.17%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.00%
CURRENT VS 3Y AVG
+73.77%
CURRENT VS 5Y AVG
+674.81%
CURRENT VS 10Y AVG
+172.88%
CURRENT VS 15Y AVG
+150.37%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+198.52%
vs the sector median at left
ADMA Biologics, Inc.
Market Cap
$2.34B
Return on Equity (ROE)
41.39%
TTM Avg
43.11%
3Y Avg
23.82%
5Y Avg
-7.20%
Market Cap
$2.33B
Return on Equity (ROE)
15.63%
TTM Avg
16.66%
3Y Avg
16.66%
5Y Avg
13.72%
Market Cap
$2.33B
Return on Equity (ROE)
-84.78%
TTM Avg
-42.91%
3Y Avg
-54.25%
5Y Avg
-44.36%
Market Cap
$2.37B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
Market Cap
$2.30B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.40B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.28B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.41B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.24B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.34B | 41.39% | 43.11% | 23.82% | -7.20% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 15.63% | 16.66% | 16.66% | 13.72% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.33B | -84.78% | -42.91% | -54.25% | -44.36% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | -38.17% | -26.66% | -25.50% | 23.47% |
| Liquidia Corporation (LQDA)vs › | $2.30B | 71.04% | -161.38% | -133.53% | -111.86% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.88% | -20.16% | -52.49% | -49.61% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 18.14% | 20.16% | 28.24% | 15.58% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | -56.71% | -50.91% | -55.48% | -35.68% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | N/A | 9.38% | 9.38% | 9.38% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.47B | -10.66% | 1.75% | 2.62% | 5.68% |
ROE
41.4%
ROA
24.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 41.39% |
| 2026-03-31 | 42.36% |
| 2025-12-31 | 30.78% |
| 2025-09-30 | 48.57% |
| 2025-06-30 | 52.45% |
| 2025-03-31 | 55.37% |
| 2024-12-31 | 56.64% |
| 2024-09-30 | 29.38% |
| 2024-06-30 | 18.48% |
| 2024-03-31 | -2.37% |
| 2023-12-31 | -20.89% |
| 2023-09-30 | -15.07% |
| 2023-06-30 | -27.45% |
| 2023-03-31 | -32.74% |
| 2022-12-31 | -43.37% |
| 2022-09-30 | -70.05% |
| 2022-06-30 | -63.93% |
| 2022-03-31 | -61.67% |
| 2021-12-31 | -50.75% |
| 2021-09-30 | -72.39% |
| 2021-06-30 | -65.96% |
| 2021-03-31 | -66.56% |
| 2020-12-31 | -85.83% |
| 2020-09-30 | -93.73% |
| 2020-06-30 | -79.89% |
| 2020-03-31 | -56.53% |
| 2019-12-31 | -184.32% |
| 2019-09-30 | -154.37% |
| 2019-06-30 | -126.75% |
| 2019-03-31 | -607.53% |
| 2018-12-31 | -332.53% |
| 2018-09-30 | -163.11% |
| 2018-06-30 | -117.38% |
| 2018-03-31 | -239.06% |
| 2017-12-31 | -108.49% |
| 2017-09-30 | -271.97% |
| 2017-06-30 | -88.37% |
| 2016-06-30 | -518.62% |
| 2015-09-30 | -344.93% |
| 2015-06-30 | -160.02% |
| 2015-03-31 | -108.07% |
| 2014-12-31 | -279.82% |
| 2014-09-30 | -194.17% |
| 2014-06-30 | -140.26% |
| 2014-03-31 | -114.37% |
| 2013-12-31 | -71.97% |
| 2013-06-30 | -789.04% |
| 2013-03-31 | -155.39% |
| 2012-12-31 | -77.48% |
| 2012-09-30 | -43.58% |
| 2012-06-30 | -12.40% |
| 2012-03-31 | -3.95% |
| 2011-03-31 | -215.45% |
